Singapore’s GIC leads $85m Series B round for China’s Harbour BioMed

Photo: Reuters

Shanghai-based pharma company Harbour BioMed has announced the closing of an $85-million Series B financing round led by Singapore sovereign wealth fund GIC.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at